ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.68
0.10%
US Tech 100
20,861.20
-1.52%
S&P 500
5,966.44
-1.18%
US Dollar vs CAD
1.44255
0.11%
Bitcoin
94,344.29
-1.40%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Genelux Corporation (GNLX) Share Price

Genelux Corporation

Genelux Corporation (GNLX)

NASDAQ
2.51
0.05
( 2.03% )
Updated: 12:52:25
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
2.51
Bid
2.46
Ask
2.51
Volume
67,617
2.41 Day's Range 2.53
1.60 52 Week Range 16.60
Market Cap
86.691M
Previous Close
2.46
Open
2.46
Last Trade
1
@
2.46
Last Trade Time
12:51:39
Financial Volume
US$ 166,522
VWAP
2.4627
Average Volume (3m)
160,349
Shares Outstanding
34,538,185
Dividend Yield
-
PE Ratio
-2.98
Earnings Per Share (EPS)
-0.82
Revenue
170k
Net Profit
-28.3M

About Genelux Corporation

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac... Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.genelux.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Genelux Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GNLX. The last closing price for Genelux was US$2.46. Over the last year, Genelux shares have traded in a share price range of US$ 1.60 to US$ 16.60.

Genelux currently has 34,538,185 shares outstanding. The market capitalization of Genelux is US$84.96 million. Genelux has a price to earnings ratio (PE ratio) of -2.98.

Ask ADVFN Intelligence (AI)

GNLX Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

December 20 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 20 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 20 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 20 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 20 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 20 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 18 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.3516.20370370372.162.532.15695692.35155519CS
4-0.21-7.720588235292.723.11492.131176242.5825973CS
120.14.149377593362.413.62.131603492.73938119CS
260.3616.74418604652.153.61.61661132.46235977CS
52-12.7-83.497698882315.2116.61.61703293.88960232CS
156-3.49-58.1666666667640.981.615224011.14202843CS
260-3.49-58.1666666667640.981.615224011.14202843CS

GNLX - Frequently Asked Questions (FAQ)

What is the current Genelux share price?
The current share price of Genelux is US$ 2.51
How many Genelux shares are in issue?
Genelux has 34,538,185 shares in issue
What is the market cap of Genelux?
The market capitalisation of Genelux is USD 84.96M
What is the 1 year trading range for Genelux share price?
Genelux has traded in the range of US$ 1.60 to US$ 16.60 during the past year
What is the PE ratio of Genelux?
The price to earnings ratio of Genelux is -2.98
What is the cash to sales ratio of Genelux?
The cash to sales ratio of Genelux is 497.96
What is the reporting currency for Genelux?
Genelux reports financial results in USD
What is the latest annual turnover for Genelux?
The latest annual turnover of Genelux is USD 170k
What is the latest annual profit for Genelux?
The latest annual profit of Genelux is USD -28.3M
What is the registered address of Genelux?
The registered address for Genelux is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Genelux website address?
The website address for Genelux is www.genelux.com
Which industry sector does Genelux operate in?
Genelux operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
INTZIntrusion Inc
US$ 1.83
(306.67%)
150.67M
HUBCWHub Cyber Security Ltd
US$ 0.0369
(269.00%)
2.23M
GTIGraphjet Technology
US$ 1.1601
(242.72%)
353.91M
AILEiLearningEngines Inc
US$ 0.5312
(228.92%)
503.21M
LITMSnow Lake Resources Ltd
US$ 1.665
(89.20%)
111.33M
NEUPNeuphoria Therapeutics Inc
US$ 4.14
(-92.25%)
879.11k
VIRXViracta Therapeutics Inc
US$ 0.14999
(-36.71%)
6.67M
PRFXPainReform Ltd
US$ 3.37
(-31.22%)
832.26k
AIREreAlpha Tech Corporation
US$ 2.6499
(-25.98%)
7.17M
BAOSBaosheng Media Group Holdings Ltd
US$ 3.35
(-24.21%)
1.02M
AILEiLearningEngines Inc
US$ 0.5312
(228.92%)
497.68M
GTIGraphjet Technology
US$ 1.1601
(242.72%)
353.71M
RGTIRigetti Computing Inc
US$ 17.8201
(15.42%)
241.4M
XTIAXTI Aerospace Inc
US$ 0.04
(0.00%)
229.43M
QSIQuantum Si Inc
US$ 3.745
(74.19%)
201.61M

GNLX Discussion

View Posts
stocktowatch stocktowatch 2 weeks ago
$GNLX Genelux_Corp Corporation to Participate in a Fireside Chat with H.C. Wainwright
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.



https://finance.yahoo.com/news/genelux-corporation-participate-fireside-chat-120100563.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
👍️0
stocktowatch stocktowatch 2 weeks ago
$GNLX November 2024 Corporate Presentation

https://investors.genelux.com/static-files/cb26a67f-274b-49ab-84cc-de52b67c4118
👍️0
stocktowatch stocktowatch 2 weeks ago
$GNLX NASDAQ Genelux 2024 Annual Stockholder Meeting


👍️0
TheFinalCD TheFinalCD 2 months ago
https://finviz.com/quote.ashx?t=GNLX&ty=c&ta=1&p=d
👍️0
stocksrising stocksrising 2 months ago
Any news for pop??
Found it….sorry, just saw


Genelux Corporation Announces
First Patient Dosed in Phase 2
Trial Evaluating Systemic
Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
GlobeNewswire
- VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-
doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer-
- Trial represents second indication in the clinic for Olvi-Vec via systemic administration -
- Interim readout expected mid-2025 -
WESTLAKE VILLAGE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) - Genelux Corporation (GNLX. NaE) , a late-stage clinical immuno-oncology company, today announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC) who have failed frontline platinum and immune checkpoint inhibitor (ICI) therapies.
👍️0
stocktowatch stocktowatch 3 months ago
$GNLX Trending up resistance in play https://schrts.co/nQTnXUut
👍️ 1 💥 1
stocktowatch stocktowatch 3 months ago
$GNLX On alert for News!? stay tuned..
👍️0
stocktowatch stocktowatch 3 months ago
$GNLX Possible Breakout! announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. The conversation with Emily Bodnar, Vice President, Equity Research and H.C. Wainwright Biotechnology Analyst, is scheduled to begin at 12:30 p.m. ET on Wednesday, September 11, 2024. A webcast link for the H.C. Wainwright Conference event will be available at https://journey.ct.events/view/d1ba765d-c21b-46c9-8197-e4dd858808f0. An archived replay will be available for approximately 90 days following the event on the company’s IR page.

https://finance.yahoo.com/news/genelux-corporation-present-h-c-200100800.html
👍️0
stocktowatch stocktowatch 4 months ago
$GNLX 1 Month chart resistance in play https://schrts.co/BWBNmgEe
👍️0
stocktowatch stocktowatch 4 months ago
$GNLX Fundamental breakout Volume recovery get in early for the big boom https://schrts.co/sGWIJqyY
👍️0
Monksdream Monksdream 4 months ago
GNLX under $3
👍️0
stocktowatch stocktowatch 4 months ago
Is Genelux (NASDAQ: $GNLX) In A Good Position To Invest In Growth? https://finance.yahoo.com/news/genelux-nasdaq-gnlx-good-position-134334395.html
👍️0
stocktowatch stocktowatch 5 months ago
$GNLX Technical chart
https://schrts.co/SjVYghqR
👍️0
stocktowatch stocktowatch 5 months ago
$GNLX Website : https://genelux.com/
👍️0
Monksdream Monksdream 5 months ago
GNLX under $3
👍️0
stocktowatch stocktowatch 5 months ago
$GNLX historical movement price and volume https://ih.advfn.com/stock-market/NASDAQ/genelux-GNLX/historical
👍️0
Monksdream Monksdream 7 months ago
GNLX new 52 week low
👍️0
Monksdream Monksdream 8 months ago
GNLX new 52 lo
👍️0
Monksdream Monksdream 9 months ago
GNLX new 52 lo
👍️0
MiamiGent MiamiGent 1 year ago
GNLX Genelux gets fast track status for Olvi-Vec in ovarian cancer
Nov. 27, 2023 3:22 PM ET Genelux Corporation (GNLX) By: Val Brickates Kennedy, SA News Editor

https://stockcharts.com/h-sc/ui?s=GNLX

Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer.

The company is currently conducting a Phase 3 registrational study of the immunotherapy in combination with platinum-based chemotherapy in patients with platinum resistant/refractory ovarian cancer.
👍️0

Your Recent History

NASDAQ
GNLX
Genelux
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads